Summary
In a blog post featured on the Commonwealth Fund’s To the Point, the Wynne Health Group sketches the current landscape of congressional drug pricing proposals and begins outlining what a final legislative package my look like. Specifically, the authors examine which measures have moved forward in the Senate, and cross-reference those with related measures advanced on the House side.